Acción 89bio (ETNB)
Empresa del sector salud. Aquí tienes el precio, un resumen del negocio y lo que conviene saber sobre 89bio en septiembre 2026.
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone.
Rendimiento del crecimiento a seis meses
Resumen del rendimiento de la acción
Calificación de los analistas
Analysts recommend buying 89bio Inc's stock with a target price of $29.83, indicating strong growth potential.
Salud financiera
89bio Inc shows strong cash generation and a solid book value per share, indicating good financial health.
Ve más acciones descargando la app GRATIS
Solo toma 60 segundos.
¿Por qué invertir con Nemo?
Cero comisiones
Opera acciones, ETF y más sin comisiones. Conserva una mayor parte de tus ganancias.
Confiable y regulado
Parte del grupo Exinity desde 2015, con más de un millón de clientes en todo el mundo.